A Metabolic Explanation of Cancer: The Bio-Energetic Theory of Carcinogenesis.
Eukaryotic mitochondria resulted from symbiotic incorporation of [alpha]-proteobacteria into ancient archaea species. During evolution, mitochondria lost most of the prokaryotic bacterial genes and only conserved a small fraction, including the encoding 13 proteins of the respiratory chain. In this process, many functions were transferred to the host cells, but mitochondria gained a central role in the regulation of cell proliferation and apoptosis, and in the modulation of metabolism. Defective mitochondria may contribute to cell transformation and cancer, diabetes, and neurodegenerative diseases. Many effects of the mitochondria depend on the modulation of respiratory rate and on the production of hydrogen peroxide and other oxidative species released into the cytosol.
All cancer cells regardless of their tissue origin express a defect in mitochondrial energy metabolism. The view of cancer as a genetic disease has been an issue of confusion and is largely responsible for the failure in treating the disease. This view of cancer as a genetic disease is based on the flawed assumption that somatic mutations cause cancer--although we should state that genomic instability is linked to respiratory insufficiency. The mitochondrial oxidative rate has to remain depressed for cell proliferation to occur; even in the presence of oxygen, energy is obtained from increased glycolysis (Warburg effect) (Antico-Arciuch et al, 2012).
It is likely that the major impediment to the effective treatment of cancer has been the confusion surrounding its origin. Most of the confusion arises from the absence of a unifying theory that integrates all aspects of the disease. We propose the Bio-Energetic Theory of Carcinogenesis as the main theory to fill this gap in the understanding of the origin of cancer (Gonzalez et al, 2012).
In general, the Bio-Energetic Theory of Carcinogenesis states that cancer originates from damage to the mitochondria that impairs the cell's capacity to generate energy with oxygen (oxidative energy production) with a concurrent increase in energy generation without oxygen. In other words, this theory states that cancer is not of genetic origin but rather a disease of metabolism.
This theory is based on the ideas proposed in 1924 by the Nobel Prize-winning German biochemist Otto Warburg. These ideas were subsequently discarded when it was discovered that cancer cells had mutations to their DNA. So, it was concluded that if cancer cells have mutations to the molecule that dictates all cellular functions, then that must be the cause of the disease.
A healthy cell produces 89% of its energy using oxygen, and 11% through non-oxidative metabolism (non-oxidative metabolism is also known as fermentation). Oxidative energy production is far more efficient than fermentation. Almost 20 times more energy is released when glucose is completely oxidized, as opposed to when it is just fermented.
The Bio-Energetic Theory of Carcinogenesis explains that the disease begins with damage to the mitochondria. The cell is then forced to shift energy production to fermentation in order to survive. So, two main characteristics of cancer are (1) damaged mitochondria and (2) increased fermentation, which are present in all cancer types. Also, the greater the degree of fermentation displayed by a given cancer, the more aggressive the cancer is. Because a tumor cell's mitochondria are damaged and, therefore, are forced to generate energy by an inefficient pathway, they need to consume much more glucose to remain viable. A glance at a PET scan, which uses a radioactive-labeled glucose analog to image cancer, provides stunning visual evidence of the necessity that tumor cells have for glucose compared to normal cells.
It is interesting that since 1885, when Freund observed that patients with malignant disease can develop spontaneous hyperglycemia (Freund et al, 1885), there has been episodic interest in the association of the altered glucose metabolism in nutrition and neoplasia (Marks et al, 1957). As early as 1924, Handel and Tadeuma summarized the findings in those days by the following statement: "A diet rich in carbohydrates has a pronounced stimulating impact on tumor growth" (Handel et al, 1924).
Emerging evidence reveals that all hallmarks of cancer can be explained by mitochondrial damage followed by a shift to non-oxidative energy metabolism. Once the oxidative energy generating capacity of the cell is impaired, the cell undergoes a dramatic transformation; it is when oncogenes are switched on, initiating and propagating the uncontrolled proliferation that is the main hallmark of cancer.
Genetics and Cancer
Most genetic changes in tumor cells are irrelevant to the origin of cancer. They can be described as an epiphenomenon of the metabolic/physiological chaos due to the less availability of cellular energy.
Genomic instability has been assumed to elicit the large number of mutations found in tumor cells, thus supporting the idea that cancer is a genetic disease. While genome changes participate in disease progression, they do not cause the disease. Cancer is a disease of defective cellular energy metabolism. Most genomic effects found in cancer arise as secondary downstream effects of defective energy metabolism (Seyfried et al, 2010).
Respiratory insufficiency precedes the genomic instability that further contributes to tumor development. Once established, this genomic derangement also contributes to further respiratory impairment, mutability, and tumor progression. Metabolic derangements precede genetic changes. It is, in essence, a process that starts as an epigenetic phenomenon that eventually changes the genotype.
The genetic mutations acquired following mitochondrial impairment unquestionably contribute to the tumor cell's features and aggressiveness but are not the cause of the disease. They appear to be of secondary consequence or an epiphenomenon to the metabolic dysfunction. While it's true that most of the agents known to cause cancer chemical carcinogens, viruses, radiation, and inflammation--can cause mutations to DNA, it is also true these agents damage cell membranes and especially the mitochondria. Once the mitochondrion is damaged, the cell reverts to fermentation to obtain energy, we can state that the cancer has begun. It is subsequent to the shift in energy metabolism that genomic instability and mutations occur (Seyfried et al, 2010). Genetic sequencing data has been unable to implicate genetic mutations as the cause of cancer; in contrast metabolic dysfunction has been shown to be present in every type of cancer, regardless of tissue of origin. In an attempt to explain the random complexity of the thousands of mutations reported in cancer, researchers claim that cancer is a collection of over 200 different diseases. We believe that cancer is just one disease, a metabolic one. It is not a collection of over 200 different diseases as the genetic theory proposes.
The genetic mutational profile of any given cancer type looks different from person to person, rendering it impossible to claim that mutations are definitely responsible for the origin of the disease. To make this issue even more confusing, the mutational profile is different from cell to cell within the same tumor, rendering drug development to target mutations next to impossible. No mutation has yet been identified that is reliably diagnostic of any type of cancer. So, we definitely see genetic changes in cancer progression but secondary to the metabolic problem, which contributes to perpetuate the malignant state.
To achieve real therapeutic progress, the true origin of the disease needs to be determined. All therapeutic progress, from prevention to treatment, must arise from a foundation of understanding of the disease.
A series of nuclear/cytoplasm transfer experiments are exceptionally important in revealing the true nature of the disease. In brief, the experiments consist of transferring the nucleus of a cancer cell into a healthy cell that has had its nucleus removed prior. The newly created hybrid cell has the genetic material of a cancer cell, with all of its defects, but now has the healthy mitochondria of a normal cell. Intuitively, if the origin of cancer is indeed due to mutations to DNA, the newly created hybrid cells that still retain all of the mutations of the cancer cell nucleus should be tumorigenic. But they were not.
These experiments were carefully executed with strict controls and were found to be very reproducible. Experiments like these provide irrefutable evidence that DNA mutations are not the origin of cancer; the damaged mitochondria are. All cells require regulated energy homeostasis to maintain their differentiated state (Elliott et al, 2012). It should be stated that mitochondrial dysfunction leads to nuclear genome instability.
In order for cells to remain viable and to perform their programmed function, they must produce energy. Membrane pumps require constant energy to maintain functionality. Most cell functions are linked to the membrane potential and to the Na+/K+/Ca+ gradients. Availability of ATP to the pumps maintains these ionic gradients. If these pumps are disrupted, cellular dysfunction will ensue. Regardless of cell type or tissue origin, cancer cells share a singular characteristic and that is abnormal energy metabolism. Energy dysregulation is the hallmark of malignant cells. Tumor cells differ from normal cells in the origin of the energy produced rather than in the amount of energy produced.
We truly believe that targeting the defective energy metabolism of tumor cells will eventually become the most effective approach to cancer management.
Another important characteristic of cell energetics is that at physiological levels reactive oxygen species (ROS), a product of oxidative phosphorylation, function as cellular messengers in intracellular signaling and regulation. It is feasible that these molecules have a role in gene regulation, especially cell division.
The shift by cancer cells from OxPhos (oxidative phosphorylation) to glycolysis, even under normoxic conditions, is called the Warburg effect. ATP production by glycolysis can be more rapid than by OxPhos, but it is less efficient in terms of molecules of ATP generated per unit of glucose. Therefore, tumor cells must increment the rate of glucose uptake. The energy efficiency of aerobic glycolysis is low, since two ATP are produced, which represents eighteen times less than the complete degradation of glucose producing 36 ATP.
Aerobic fermentation involves elevated glucose uptake with lactic acid production in the presence of oxygen. Warburg stated that irreversible damage to respiration was the prime cause of cancer (Warburg et al, 1931; Warburg et al 1956; Warburg et al, 1969). Warburg was the first to describe in detail the dependence of cancer cells on glucose and glycolysis in order to maintain viability following respiratory damage (Warburg et al, 1931; Warburg et al 1956; Warburg et al, 1969). Warburg considered energy as the central issue of carcinogenesis. Warburg considered fermentation as the formation of lactate from glucose in the absence of oxygen. This type of energy pathway is also utilized in mammalian embryos and muscle cells during strenuous exercise. Here, pyruvate instead of entering the TCA cycle is reduced to lactate in the absence of oxygen. Lactate fermentation generates NAD+ that can be used as an electron acceptor. In cancer cells, this fermentation occurs even in the presence of oxygen.
Lactate is basically a metabolic waste from incomplete oxidation of glucose; nevertheless, it can be recycled at a high energetic cost in the Cori cycle. The Cori cycle produces two ATPs at a cost of six ATPs, which in part explains the cachexia syndrome in patients with advanced cancer. Most lactate enters the blood stream where it is used to synthesize glucose in the liver. Warburg attributed this aerobic fermentation in tumor cells to respiratory damage or respiratory insufficiency. In other words, damaged mitochondria.
One relevant issue pertaining to the Warburg hypothesis is that mitochondrial amino acid fermentation confuses the boundaries between normal respiration and fermentation; this particular issue can bring light to much of the controversy surrounding this hypothesis, since it can give a false impression of mitochondrial oxidative phosphorylation.
Cancer cells not only consume glucose in excess but also amino acids, especially glutamine, derived from muscle proteolysis. Glutamine, which is the preferential mode of transportation of blood nitrogen, provides amine groups for several biosynthetic processes, such as purine and pyrimidine bases synthesis.
Cancer cells that rely on glutamine for energy production are able to produce ATP through non-oxidative processes in the mitochondria. Glutamine metabolism increases ammonia in the extracellular environment. Ammonia can neutralize acidity from glycolytic lactate production (Baggetto et al, 1992; Kelly et al, 1974). So, caution is therefore necessary in using pH as an indicator of lactate production (fermentation) in cancer cells that use glutamine as fuel. This type of pseudo-respiration has the biochemical characteristics of normal respiration but does not involve ATP synthesis through oxidative phosphorylation (OxPhos). The energy is derived from amino acid fermentation. Glucose and glutamine interact synergistically to drive tumor cell fermentation (Seyfried et al, 2010; Seyfried et al, 2011).
The external pH of solid tumors is acidic as a consequence of increased metabolism of glucose and poor perfusion. Acid pH has been shown to stimulate tumor cell growth, invasion, and metastasis.
Mitochondrial Uncoupling and Cancer
Uncoupling involves dissipation of the mitochondrial proton gradient. Uncoupling produces heat instead of ATP. Heat production is greater in less differentiated tumor cells (Seyfried et al, 2010). The greater heat production in the less differentiated cells supports the hypothesis that mitochondrial uncoupling is greater in cancer cells that are more malignant. Moreover, heat production is correlated with increased glucose consumption and lactic acid production (Nittinger et al, 1990). The greater the uncoupling, the greater will be the need to produce energy through substrate level phosphorylation (aerobic glucose fermentation).
While reduced oxygen uptake may be indicative of reduced OxPhos, increased oxygen uptake may or may not be indicative of increased OxPhos and ATP production (Jahnke et al, 2010; Samudio et al, 2009; Ramanathan et al, 2005). In this sense, oxygen consumption in tumor cells could provide misinformation of the true respiratory capacity of these cells.
Mitochondrial dysfunction can be characterized by any of three ways: 1) by not having enough mitochondria, 2) by not having adequate substrate or nutrient co-factors needed for oxidative phosphorylation, or 3) by acquired dysfunction in the ATP synthesis machinery.
Mitochondria and Differentiation
Mitochondria provide the energy needed to maintain cellular differentiation. The total number of mitochondria in tumor cells is significantly lower that the number of mitochondria in normal cells (Seyfried et al, 2010). The total respiratory capacity of tumor mitochondria is lower than that of mitochondria of normal cells (Seyfried, 2010; Seyfried et al, 2014). Abnormalities in mitochondrial size and shape are correlated with mitochondrial dysfunction (Benard et al, 2008; Shapovalov et al, 2011; Mates et al, 2009). Highly malignant tumors do not have mitochondria of normal morphology and number (Seyfried et al, 2010). The greater the degree of mitochondrial morphological abnormality, the greater the degree of malignancy (Pedersen et al, 1978). Respiratory impairment requires enhanced fermentation to prevent apoptosis (Seyfried et al, 2010). Moreover, enhanced fermentation prevents differentiation and is linked to uncontrolled cell proliferation (Seyfried et al, 2010).
ATP synthesis through mitochondrial fermentation involving substrate level phosphorylation could give the false impression that tumor mitochondria are producing ATP through respiration (Seyfried et al, 2010). The failure to recognize this type of ATP production by a non-oxidative process in tumor mitochondria contributes to the confusion surrounding the Warburg hypothesis of cancer and explains the basis of its rejection (Denny et al, 2010). Stem cells are described to have minimal mitochondrial structures with few cristae. Increased mitochondrial function is important for differentiation.
Cellular Communication Between the Mitochondrion and the Nucleus and Cancer
There is a development of bidirectional signaling mechanisms between the mitochondrion and nucleus. Communication and signaling pathways from nucleus to the mitochondria are ancient, early developed communication routes that coordinate the mitochondrial response to changing intracellular microenvironment and act as sensor mechanisms governing the cellular response to external stimuli (Grabacka et al, 2014). Evolution had led to the transfer of increasing numbers of genes encoding the proteins crucial for respiration to nuclear genome. Mitochondrial DNA encodes only 13 subunits of respiratory complexes I, III, IV, and V, although they are indispensable for electron transport and respiration. Nuclei have taken over the significant control expression of respiratory complexes but also numerous proteins involved in the maintenance and replication of mtDNA or enzymatic machinery driving various metabolic pathways in the mitochondrial matrix (Scarpulla,2002, Scarpulla,2002 (B)). Communication and signaling pathways from mitochondria to nucleus evolved as a cellular adaptation to factors and conditions that impair mitochondrial functions. When mitochondria emit such a signal to the nucleus, the cell can switch on repair programs and reorganize metabolism to keep energetic homeostasis (Guha and Avadhani, 2013). This pathway can be induced by defects in the respiratory chain, accumulation of mtDNA mutations, alterations in mtDNA copy number, or loss of membrane potential.
Lipids and Cancer
Lipids may have a further relevant role in carcinogenesis related to the mitochondrial membrane. OxPhos capability is linked to the structural integrity of mitochondrial cristae (Frey et al, 2000; Putignani et al, 2008; Paumard et al, 2008). Lipids maintain the integrity of these bio-membranes. Abnormalities in lipids can compromise mitochondrial function. Mitochondrial lipid abnormalities are common in all tumors. Altered mitochondrial lipids reduce the efficiency of OxPhos, requiring increased energy production through substrate level phosphorylation.
Phospholipids and Cancer
Cardiolipin is known as the signature phospholipid of mitochondria. It is responsible for a wide range of mitochondrial functions. Abnormalities in the structure of cardiolipin have been identified in tumor cells (Seyfried et aI, 2014).
It is important to clarify that the in-vitro growth environment produces lipid and electron transport abnormalities in mitochondria in both tumorigenic and non-tumorigenic cells (Kiebish et al, 2009). A failure to recognize this fact could confuse data interpretation related to energy metabolism. Caution should be taken when comparing energy metabolism of malignant vs non-malignant cells in tissue culture environments since they do not truly replicate the in vivo environmental growth conditions. This could have been the problem interpreting key experiments defining the metabolic origin of cancer.
Mitochondrial Oncology: The Next Frontier
Once considered exclusively the cell's powerhouse, mitochondria are now recognized to perform multiple essential functions beyond energy production, impacting most areas of cell biology and medicine especially cancer.
The customary cancer therapeutic strategy is based on cancer cell killing, which has not proven to be successful. Treatment of cancer should be based on essential and specific differences between healthy cells and cancer cells.
Protocol for Cancer
If we are correct that cancer is truly a metabolic disease, the therapeutic implications are huge. First, if we are correct, it would explain why virtually no progress has been made in reducing the death rates from cancer since 1950. Second, it opens up many possibilities for new avenues of treatment. The first place to start is manipulating the macromolecules of our diet by implementing a low carbohydrate diet (Paleo or ketogenic diet), starving the cancer cells of glucose. In virtually every experiment in which the ketogenic diet has been tested in mice, tumor growth rates have slowed dramatically. It appears that the ketogenic diet is able to put cancer cells under significant metabolic stress allowing additional non-toxic therapies, like intravenous vitamin C, hyperbaric oxygen, and mitochondrial correction to push the cells further over the edge. We propose that combining these non-toxic treatments would provide a powerful, synergistic anti-cancer effect.
Potential concern may arise regarding the use of a diet therapy for cancer patients susceptible to cachexia. While low carbohydrate or ketogenic diets promote weight loss in overweight individuals, they are also known to spare muscle wasting during conditions of energy restriction and starvation (Manninen et al, 2006; Cahill et al, 2006; Veech et al, 2004; Volek et al, 2002).
The anti-cachexia effects of the ketogenic diet are not surprising when considering a metabolic switch to fat metabolism and subsequent ketosis evolved as a method of sparing protein during prolonged fasting or starvation (Veech et al, 2001; Wu et al, 1988). It makes sense that dietary-induced therapeutic ketosis in a cancer patient would prevent muscle wasting similarly as it does with athletes undergoing intense exercise (Paoli et al, 2012).
Human studies of high-dose intravenous vitamin C in patients with cancer have shown improved quantity and quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss (Gonzalez et al, 2014).
In relation to hyperbaric oxygen (HB02T), there are a substantial number of studies indicating that HB02T can induce marked anti-cancer effects in vitro and in animal and human studies alike (Daruwalla et al, 2006; Moen et al, 2012; Al-Waili et al, 2005).
Considering mitochondria a possible therapeutic target, two different approaches can be suggested: a) to stimulate mitochondrial activity, in order to restore metabolic pathways characteristic of nonmalignant cells, and/or b) to stimulate mitochondrial dependent cell death pathways. Both ways suppress cancer.
A strategic problem in cancer therapy is how to selectively activate apoptosis in transformed cells. A successful way to eliminate cancer cells can be based on the ability of anti-cancer treatment to activate apoptotic pathways, which are suppressed in tumor cells. This may be achieved by partially restoring damaged mitochondria.
Mitochondrial dysfunction is a primary cause of cancer, and biochemical and genetic deviations develop as consequent events. Cancer therapeutic strategy targeting mitochondria may restore normal physiological functions of mitochondria and open the apoptotic pathway.
Mitochondrial Enhancers (Co-Factors) for Mitochondrial Correction
If the mitochondria are denied the basic nutrition they need to function, they cease to function normally. For their functioning, mitochondria need energy substrates and oxygen, but also cofactors (non-protein compounds, vitamins, and minerals needed for enzyme activity) to perform essential biochemical tasks. Insufficiencies in these cofactors are associated with diseases including cancer; this may result from their role in energy metabolism but also from specific metabolic alterations, such as the formation of toxic metabolites, altered mechanisms that protect against reactive oxygen species, etc. Among the essential cofactors facilitating energy metabolism are B vitamins and minerals such as magnesium. Additional important cofactors are acetyl-L-carnitine, r-alpha-lipoic-acid, coenzyme Q10, phospholipids, vitamin C, vitamin D, mixed tocopherols and tocotrienols, creatine, NADH, NAC, omega-3, resveratrol, arginine, quercetin, Shilajit, PQQ, and curcumin.
In summary, the information presented herein supports the concept that cancer originates from damage to the mitochondria rather than from damage to the genome. The genomic damage in tumor cells follows, rather than precedes, the disturbances in cellular respiration.
Al-Waili NS, et at. (2005). Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Medical Science Monitor, 11: RA279-289.
Antico Arciuch VG, et al. (2012). Mitochondrial regulation of cell cycle and proliferation. Antioxidants and Redox Signaling, 16(10), 1150-1180.
Baggetto LG. (1992). Deviant energetic metabolism of glycolytic cancer cells. Biochimie, 74, 959-974.
Benard G, Rossignol R. (2008). Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxidants and Redox Signaling, 10, 1313-1342.
Cahill G. (2006). Fuel metabolism in starvation. Annual Review of Nutrition, 26: 1-22.
Daruwalla J, Christophi C. (2006). Hyperbaric oxygen therapy for malignancy: a review. World Journal of Surgery, 30, 2112-2143.
Denny CA, et al. (2010). Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington's disease. Journal of Neurochemistry, 115(3), 748-758.
Elliott RL, et al. (2012). Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. Breast Cancer Research and Treatment, 136,347-354.
Freund E. (1885). Zur Diagnose des Carzinoms. Vorlaufige Mittheilung. Wien Med Bl, 8,267.
Frey TG, Mannella CA. (2000). The internal structure of mitochondria. Trends in Biochemical Sciences, 25(7), 319-324.
Gonzalez MJ, Miranda-Massari JR. (2014). New Insights on Vitamin C and Cancer. Springer Briefs in Cancer Research. Springer-Verlag, New York.
Gonzalez MJ, et al. (2012). The bio-energetic theory of carcinogenesis. Medical Hypotheses, 79(4) 433-439.
Grabacka MM, et al. (2014). Phytochemical Modulators of Mitochondria: The Search for Chemopreventive Agents and Supportive Therapeutics. Pharmaceuticals, 7, 913-942.
Guha M, Avadhani NG. (2013). Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion, 13, 577-591.
Handel M, Tadenuma, K. (1924). Uber die Beziehung des Geschwul5twachstums zur Ernahrung und zum Stoffwechsel. II. Mitteilung. Versuche zur Frage der Bedeutung der Kohlenhydrate fur das Wachstum des Rattencarzinoms. Z Krebsforsch, 21,288-293.
Jahnke VE, et al. (2010). Evidence for mitochondrial respiratory deficiency in rat rhabdomyosarcoma cells. PLoS One, 5(1), e8637.
Kelly MA, Kazemi, H. (1974). Role of ammonia as a buffer in the central nervous system. Respiration Physiology, 22,345-359.
Kiebish MA, et al. (2009). In vitro growth environment produces lipidomic and electron transport chain abnormalities in mitochondria from non-tumorigenic astrocytes and brain tumours. ASN Neurology, 1(3), pii, e00011.
Manninen AH. (2006). Very-low-carbohydrate diets and preservation of muscle mass. Nutrition and Metabolism 3: 9.
Marks PA, Bishop JS. (1957). The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. Journal of Clinical Investigation, 36, 254-264.
Mates JM, et al. (2009). Glutamine homeostasis and mitochondrial dynamics. International Journal of Biochemistry and Cell Biology, 41(10), 2051-2061.
Moen I, Stuhr LE. (2012). Hyperbaric oxygen therapy and cancer-a review. Targeted Oncology, 1, 233-242.
Nittinger J, et al. (1990). Microcalorimetric investigations on human leukemia cells-Molt 4. Biology of the Cell, 70(3), 139-142.
Paoli A, et al. (2012). Ketogenic diet does not affect strength performance in elite artistic gymnasts. Journal of the International Society of Sports Nutrition, 9, 34.
Paumard P, et al. (2002). The ATP synthase is involved in generating mitochondrial cristae morphology. European Molecular Biology Organization Journal, 21(3), 221-230.
Pedersen PL, (1978). Tumor mitochondria and the bioenergetics of cancer cells. Progress in Experimental Tumor Research, 22,190-274.
Putignani L, et al. (2008). Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Research and Treatment, 110(3), 439-452.
Ramanathan A, et al. (2005). Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proceedings of the National Academy of Sciences USA, 102(17), 5992-5997.
Samudio I, et al. (2009). Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Research, 69(6), 2163-2166.
Scarpulla RC. (2002). Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta, 1576, 1-14.
Scarpulla RC. (2002). Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene, 286, 81-89 (B).
Seyfried TN, et al. (2014). Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 35(3), 515-527.
Seyfried TN, Shelton LM. (2010). Cancer as a metabolic disease. Nutrition and Metabolism (Lond), 7,7,
Seyfried TN. (2011). Mitochondrial glutamine fermentation enhances ATP synthesis in murine glioblastoma cells. Proceedings of the 102nd Annual Meeting of the American Association of Cancer Research, Orlando, FL
Shapovalov Y, et al. (2011). Mitochondrial dysfunction in cancer cells due to aberrant mitochondrial replication. Journal of Biological Chemistry, 286(25), 22331-22338.
Veech RL. (2004). The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70, 309-319.
Veech RL, et al. (2001). Ketone bodies, potential therapeutic uses. International Union of Biochemistry and Molecular Biology Journal, 51, 241-247.
Volek J, et al. (2002). Body composition and hormonal responses to a carbohydrate-restricted diet. Metabolism: Clinical and Experimental, 51, 864-870.
Warburg O. (1931). The Metabolism of Tumors. New York: Richard R. Smith.
Warburg O. (1956). On the origin of cancer cells, Science, 123, 309-314.
Warburg O. (1969). Revised Lindau Lectures: The prime cause of cancer and prevention. Parts 1 & 2. In Burk D. Editor. Meeting of the Nobel Laurates Lindau, Lake Constance, Germany: Triltsch.
Wu GY, Thompson JR. (1988). The effect of ketone bodies on alanine and glutamine metabolism in isolated skeletal muscle from the fasted chick. The Biochemical journal, 255, 139-144.
by Michael J. Gonzalez (1), DSc, NMD, PhD, FACN, and Jorge Duconge (2), PhD
University of Puerto Rico, Medical Sciences Campus, School of Public Health (1) and School of Pharmacy (2) RECNAC 2 Project (San Juan, Puerto Rico)
Dr. Michael J. Gonzalez, CNS, DSc, NMD, PhD, is professor at the nutrition program, School of Public Health in the medical sciences campus, University of Puerto Rico, and adjunct faculty at the University of Western States And EDP University. He is currently co-director of RECNAC II project, and research director of the InBioMed Project Initiative, leaders in the development of non-toxic chemotherapy treatments for cancer. The findings of their work with intravenous vitamin C as an anti-cancer agent, published in 2002, were confirmed by the NIH in 2005. They published the first Phase i clinical study utilizing intravenous vitamin C for treatment of terminal cancer patients in 2005, and also published in 2005 the most comprehensive review on vitamin C and cancer, as a follow-up on the work of Dr. Linus C. Pauling.
Dr. Gonzalez is a Fellow of the American College of Nutrition and has authored over 200 scientific publications as well as the books / Have Cancer: What Should I Do? (2009) and New Insights on Vitamin C and Cancer (2014). He serves as a member on multiple scientific editorial boards. He has also served as consultant for several companies where he has been responsible for designing formulations of nutritional supplements and pharmaceutical products.
Dr. Gonzalez has obtained several research awards for his work on nutrition and cancer. He is one of the first Hispano-Americans and Puerto Rican to be inducted to the International Hall of Fame of Orthomolecular Medicine in April 2016.
Jorge Duconge, PhD, is professor at the School of Pharmacy, University of Puerto Rico, with more than 15 years of experience in teaching and scholarly activities. He performs research in the area of pharmacogenomics and DNA-guided personalized medicine. He also has experience in conducting pharmacokinetics and pharmacodynamic studies.
|Printer friendly Cite/link Email Feedback|
|Author:||Gonzalez, Michael J.; Duconge, Jorge|
|Date:||Aug 1, 2018|
|Previous Article:||Hyperthermia Therapy.|
|Next Article:||Plechner Findings Presented at International Integrative Oncology Convention.|